NA
TVRD

NewEdge Advisors’s Tvardi Therapeutics TVRD Stock Holding History

NewEdge Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8
Closed -$312 – 4423
2025
Q3 		$312 Buy
+8
New +$228 ﹤0.01% 3984
2025
Q1 		– Sell
-32
Closed -$594 – 4130
2024
Q4 		$594 Hold
32
– – ﹤0.01% 3640
2024
Q3 		$359 Hold
32
– – ﹤0.01% 3640
2024
Q2 		$301 Hold
32
– – ﹤0.01% 3621
2024
Q1 		$1.06K Hold
32
– – ﹤0.01% 3484
2023
Q4 		$868 Hold
32
– – ﹤0.01% 3482
2023
Q3 		$1.96K Buy
+32
New +$3K ﹤0.01% 3052
2023
Q1 		– Sell
-6
Closed -$3 – 4216
2022
Q4 		$3 Buy
+6
New +$2.28K ﹤0.01% 3917

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

NewEdge Advisors's TVRD Position: Q4 2025 in Review

NewEdge Advisors sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 8 shares — an estimated $312 sold.

NewEdge Advisors first reported a position in TVRD in Q4 2022 and held it in 8 quarters. The position peaked at $1.96K in Q3 2023. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • NewEdge Advisors reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 8 Tvardi Therapeutics shares in Q4 2025, an estimated $312.
  • NewEdge Advisors first reported a position in Tvardi Therapeutics in Q4 2022 and held it in 8 quarters.
  • NewEdge Advisors's Tvardi Therapeutics position peaked at $1.96K in Q3 2023.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.